Percutaneous mitral valve therapy: when? Which patients?
OBJECTIVE
Transcatheter management of valvular heart disease is an emerging area of intense interest. Patients with mitral regurgitation present a large clinical unmet need for therapeutic advances.


RESULTS
A large randomized, pivotal trial of one device, which performs an edge-to-edge repair, has recently completed enrollment and is awaiting all patients to reach the primary clinical endpoint. A host of other devices are still in preclinical or early clinical feasibility trials after having undergone device iteration. Clinical trials with two devices have been stopped because of disappointing early results.


CONCLUSIONS
Although the field of transcatheter treatment of aortic stenosis is proceeding at a brisk pace with commercial approval of two devices in Europe, percutaneous treatment of mitral regurgitation has progressed at a much more measured pace because of varying cause of the disease, complexity of valvular anatomy, imaging, and delivery issues.
Mack
Michael
M
Heart Hospital Baylor Plano, 7777 Forest Lane, Dallas, TX, USA. mmack@csant.com
D054326:Coronary Sinus / Q000601:surgery; D006801:Humans; D019060:Minimally Invasive Surgical Procedures / Q000295:instrumentation; D008944:Mitral Valve Insufficiency / Q000503:physiopathology / Q000601:surgery*